1-8 of 8
Ching Ching Leow
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor

Free
Jennifer Woyach, Lugui Qiu, Sebastian Grosicki, Tomasz Wrobel, Marcelo Capra, Jaroslaw Czyz, Shuhua Yi, Ki-Seong Eom, Anna Panovská, Wojciech Jurczak, Kamel Laribi, Lutz Jacobasch, Ross Baker, Richy Agajanian, Alejandro Berkovits, Muhit Özcan, Stephane Lepretre, Catherine Coombs, Paula Cramer, Katharine Lewis, Marisa Hill, Katherine Bao, Yuanyuan Bian, Amy Ruppert Stark, Ching Ching Leow, William Wierda
Journal: Blood
Blood (2025) 146 (Supplement 1): 683.
https://doi.org/10.1182/blood-2025-683
Published: 2025
Journal Articles

A first-in-human Phase 1 trial of LY4152199, a B-cell activation factor receptor (BAFF-R) T-cell engager bispecific antibody, in patients with previously treated B-cell malignancies (BAF_FRontier-1 Trial in Progress)

Free
Krish Patel, Jennifer Crombie, Tycel Phillips, Michael Dickinson, Toby Eyre, Chan Cheah, Stephen Schuster, Nirav Shah, Georg Lenz, Laurie Sehn, Donald Tsai, Erica Johnston, Sonya Chapman, Hongmei Han, Minna Balbas, Ching Ching Leow, Gilles Salles
Journal: Blood
Blood (2025) 146 (Supplement 1): 5524.
https://doi.org/10.1182/blood-2025-5524
Published: 2025
Journal Articles

Pirtobrutinib outcomes in second-line (2L) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after first-line (1L) cBTKi therapy: A pooled analysis from the BRUIN LOXO-BTK-18001 and BRUIN CLL-321 studies

Free
Toby Eyre, Matthew S Davids, Jeff Sharman, Paul Barr, Catherine Coombs, Wojciech Jurczak, Koji Izutsu, Meghan Thompson, William Wierda, Ying (denise) Wang, Marisa Hill, Donald Tsai, Ching Ching Leow, Sarang Abhyankar, Paolo Ghia, Jennifer Woyach
Journal: Blood
Blood (2025) 146 (Supplement 1): 5670.
https://doi.org/10.1182/blood-2025-5670
Published: 2025
Journal Articles

LY4152199, a First-in-Class BAFF-RxCD3 Bispecific Antibody for the Treatment of B Cell Malignancies

Free
Wei Yang, Colleen Burns, Kevin Lindquist, Julie Dobkin, Hee Rae Shin, Cindy Nguyen, Xiaodong Huang, Whitney Helms, Nicholas Arce, Yvonne Mak, Audrey Au, Abraham Abouzeid, Marta Witek, Ching Ching Leow, Xueqian Gong, Mohan Srinivasan, Joshua I. Park, Kyla Driscoll, Andrew Hass, Rikke Holmgaard, Omar Duramad, Kristin Bedard
Journal: Blood
Blood (2024) 144 (Supplement 1): 2785.
https://doi.org/10.1182/blood-2024-200316
Published: 2024
Journal Articles

BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Free
Jeff P. Sharman, Talha Munir, Sebastian Grosicki, Lindsey Roeker, John M. Burke, Christine I Chen, Norbert Grzasko, George Follows, Zoltán Mátrai, Alessandro Sanna, Shuhua Yi, Ru Feng, Vu Minh Hua, Jadwiga Holodja, Wojciech Jurczak, Matthias Ritgen, Lu-Gui Qiu, Francesc Bosch, Catherine C. Coombs, Katherine Bao, Vishalkumar Patel, Bin Liu, Livia Compte, Ananya Guntur, Ying (Denise) Wang, Marisa Hill, Ching Ching Leow, Paolo Ghia, Paul M Barr
Journal: Blood
Blood (2024) 144 (Supplement 1): 886.
https://doi.org/10.1182/blood-2024-198147
Published: 2024
Journal Articles

BRUIN CLL-313: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Free
Wojciech Jurczak, Caroline Dartigeas, Marta Coscia, Peter S. Ganly, Ghassan Al-Jazayrly, Chunxiao Wang, Katherine Bao, Ching Ching Leow, Safi Shahda, Pier Luigi Zinzani
Journal: Blood
Blood (2021) 138 (Supplement 1): 3732.
https://doi.org/10.1182/blood-2021-145938
Published: 2021
Journal Articles

BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Free
Jeff P. Sharman, Wojciech Jurczak, Catherine C. Coombs, Marisa Hill, Denise Wang, Nora C. Ku, Ananya Guntur, Safi Shahda, Ching Ching Leow, Paolo Ghia, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 3736.
https://doi.org/10.1182/blood-2021-145926
Published: 2021
Journal Articles

BRUIN CLL-322: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib Plus Venetoclax and Rituximab Versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in Progress)

Free
Anthony R. Mato, William G. Wierda, John M. Pagel, Matthew S. Davids, Pier Luigi Zinzani, Yi Lu, Hui Liu, Safi Shahda, Ching Ching Leow, Constantine S. Tam, Jennifer A. Woyach, Toby A. Eyre
Journal: Blood
Blood (2021) 138 (Supplement 1): 3742.
https://doi.org/10.1182/blood-2021-145936
Published: 2021